Venture
Affiliations
New York University
Technologies
Therapeutic
Indication
Basic Research
Clinical Research
Dermatology
Drug Discovery
Fibrosis
Personalized Medicine
Regenerative Medicine
Website
www.calregeninc.comAdditional Information
Women Founded
CalRegen, Inc is a start-up biotechnology company formed on the discovery of calreticulin (CRT), as a novel biotherapeutic that has unique, diverse and broad ranging tissue regenerative qualities that will be developed for different indications including chronic wound healing, epidermal appendage (hair follicle) neogenesis, improving the cosmetic architecture of the skin, and healing of ophthalmic ulcers.
CalRegen, Inc. Team:
Executive Leadership:
Leslie I Gold, PhD, Founder, CSO
Glenn Cornett, MD, PhD, CEO
Board:
Aron Wahrman, MD, MBA,MHCDS, FACS
Mark P Solomon, MD
Marek Michalak, PhD, Founder
Eric Hermann, Chair, Founder
Dennis Hranitzky, JD, Dechert, LLP Scientific Advisory Board
Elma Hawkins, PhD, Advisor